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Abstract
Hermansky-Pudlak syndrome (HPS), a rare autosomal recessive disorder, manifests with 
oculocutaneous albinism and a bleeding diathesis. However, severity of disease can be variable 
and is typically related to the genetic subtype of HPS; HPS type 6 (HPS-6) is an uncommon 
subtype generally associated with mild disease. A Caucasian adult female presented with a history 
of severe bleeding; ophthalmologic examination indicated occult oculocutaneous albinism. The 
patient was diagnosed with a platelet storage pool disorder, and platelet whole mount electron 
microscopy demonstrated absent delta granules. Genome-wide SNP analysis showed regions of 
homozygosity that included the HPS1 and HPS6 genes. Full length HPS1 transcript was amplified 
by PCR of genomic DNA. Targeted next-generation sequencing identified a novel homozygous 
missense variant in HPS6 (c.383T>C; p.V128A); this was associated with significantly reduced 
HPS6 mRNA and protein expression in the patient’s fibroblasts compared to control cells. These 
findings highlight the variable severity of disease manifestations in patients with HPS, and 
illustrate that HPS can be diagnosed in patients with excessive bleeding and occult oculocutaneous 
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albinism. Genetic analysis and platelet electron microscopy are useful diagnostic tests in 
evaluating patients with suspected HPS.
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Introduction:
Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by 
improper formation, processing, or trafficking of lysosome-related organelles, including 
melanosomes and platelet delta granules (Huizing, 2008). Ten genetic subtypes of HPS have 
been identified; eight are associated with genes encoding proteins in the Biogenesis of 
Lysosome-related Organelles Complex (BLOC)-1 (HPS-7, HPS-8, HPS-9), BLOC-2 
(HPS-3, HPS-5, HPS-6), or BLOC-3 (HPS-1, HPS-4), and two are associated with genes 
encoding subunits of the Adaptor Protein-3 complex (HPS-2, HPS-10)(Huizing, 2017).
Cellular defects in HPS lead to diverse disease manifestations, including oculocutaneous 
albinism and a bleeding tendency secondary to a platelet storage pool deficiency (Huizing, 
2008; Huizing, 2017; Gahl, 1998). Granulomatous colitis resembling Crohn’s disease can 
affect a subpopulation of patients with HPS, and some disease manifestations are limited to 
specific HPS subtypes (Huizing, 2017). For example, pulmonary fibrosis develops in 
patients with HPS-1, -2, and -4, and immunodeficiency with natural killer cell dysfunction 
and neutropenia manifest in patients with HPS-2 (Huizing, 2017; Gochuico, 2012; Gil-
Krzewska, 2017).
In this study, we report a patient who presented with severe bleeding tendency. Although 
oculocutaneous albinism was subclinical, ophthalmologic examination showed mild 
pigmentation defects and poor foveal development. A novel homozygous missense variant in 
HPS6 associated with absent platelet delta granules and reduced cellular levels of HPS6 
mRNA and protein was identified in this patient.
Materials and Methods:
Editorial Policies and Ethical Considerations
The patient provided written informed consent to protocols 95-HG-0193 (clinicaltrials.gov 
NCT00001456, “Clinical and Basic Investigations into Hermansky-Pudlak Syndrome”) and 
04-HG-0211 (clinicaltrials.gov NCT00084305, “Procurement and Analysis of Specimens 
from Individuals with Pulmonary Fibrosis”). The research was conducted prospectively; the 
clinical studies were approved by the institutional review board of the National Human 
Genome Research Institute.
Clinical testing was performed at Regional Cancer Center, Johnson City, Tennessee and the 
National Institutes of Health Clinical Center, Bethesda, Maryland. Platelet aggregation was 
measured by the absorbance method using the AggRam system (Helena Laboratories, 
Beaumont, TX). High-resolution computed tomography scans of the chest, pulmonary 
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function tests, and platelet electron microscopy were performed as described (Rouhani, 
2009; Ferreira, 2017).
Genetic Testing
Next Generation Sequencing (NGS) was performed in a Clinical Laboratory Improvement 
Amendments (CLIA)-certified laboratory using a targeted panel (Agilent Technologies, 
Santa Clara, CA) encompassing 9 HPS genes (i.e., HPS1, AP3B1, HPS3, HPS4, HPS5, 
HPS6, DTNBP1, BLOC1S3, BLOC1S6). Large scale single-nucleotide polymorphism 
(SNP) analysis was performed on genomic DNA using HumanOmniExpress DNA Analysis 
BeadChip (Illumina, San Diego, CA) and GenomeStudio software (Illumina) as described 
(Bryan, 2017). PCR of HPS1 using genomic DNA was performed using Platinum™ Pfx 
DNA Polymerase according to manufacturer’s instructions (Invitrogen, Carlsbad, CA).
Quantitative Real-time PCR and Western Blot Analysis for HPS6
Fibroblasts were cultured from a forearm skin biopsy as described (Stephen, 2017). Dermal 
fibroblasts from two healthy volunteers served as normal controls; dermal fibroblasts from 3 
adults with HPS-1 served as BLOC-3 complex controls. Experiments were performed in 
triplicate.
Total RNA and protein were isolated (Stephen, 2017). Quantitative real-time PCR (qPCR) 
was performed using TaqMan primers specific for HPS6 (Thermo Fisher, Waltham, MA), 
and cDNA from the patient and controls was amplified using TaqMan universal PCR master 
mix (Thermo Fisher) as described (Stephen, 2017). Results were normalized with expression 
of RFLP13a (Thermo Fisher) and analyzed. Western blot analysis was performed as 
described (Stephen, 2017). Membranes were incubated overnight at 4°C with rabbit 
monoclonal anti-HPS1 antibody (Abcam, Cambridge, UK), rabbit polyclonal anti-HPS4 
antibody (Santa Cruz Biotechnology Inc., Dallas TX), rabbit polyclonal anti-HPS6 antibody 
(Origene Technologies Inc., Rockville, MD), or mouse monoclonal anti-β-actin antibody 
(Sigma-Aldrich, St. Louis, MO). Densitometry analysis was performed using the Odyssey® 
imaging system; results were normalized to mean HPS6 protein expression in fibroblasts 
from two normal controls.
Statistical Analysis
Data shown are mean ± standard error of the mean. Student’s t-test was used to analyze 
significance of difference between means (GraphPad Prism, San Diego, CA).
Results:
Phenotypic Features
The patient is a 58-year old Caucasian woman with a long history for excessive bleeding and 
no known oculocutaneous albinism. Her pigmentation darkens with exposure to sunlight. 
She reported easy bruising and prolonged epistaxis. She was treated with blood product 
transfusions for severe menorrhagia, hemorrhage following vaginal delivery requiring 
admission to an intensive care unit, and prolonged gastrointestinal bleeding with 
hemodynamic instability after gastric polypectomy via esophagogastroduodenoscopy. She 
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also experienced intermittent episodes of lower gastrointestinal bleeding of unknown 
etiology. Colonoscopy showed no evidence of inflammatory bowel disease and incidental 
findings of 2 small polyps. Polypectomies caused prolonged lower gastrointestinal bleeding. 
Initially considered to have von Willebrand's disease, the patient’s von Willebrand factor 
antigen was normal, and she was subsequently diagnosed with a platelet storage pool defect.
Family history is notable for consanguinity. The patient’s parents are second and third 
cousins (Figure 1A). One brother had easy bruising; her other relatives, including her child, 
did not have albinism or excessive bleeding.
Physical examination was notable for light-colored hair, eyes, and skin. Best corrected visual 
acuity measured 20/25 and 20/40 in the right and left eyes, respectively. Although she did 
not have nystagmus, she had mild iris transillumination defects, minimal pigmentation of the 
peripheral retina, and a poorly developed fovea (Figures 1B-C). Optical coherence 
tomography demonstrated loss of the foveal depression, no outer segment lengthening 
relative to the parafoveal outer nuclear layer, and no extrusion of the plexifom layers, 
consistent with grade 3 foveal hypoplasia (Figure 1D)(Thomas, 2011). Cardiovascular, 
pulmonary, abdominal, and neurological findings were normal. There were no detectable 
petechiae, ecchymoses, or hematomas.
Laboratory testing revealed normal white blood count, hemoglobin, prothrombin time, 
partial thromboplastin time, factor VIII activity, and von Willebrand factor activity and 
antigen. Platelet count was 158 × 103/ul [173-369 × 103/uL]. Platelet function assay showed 
prolonged closure time in response to epinephrine (>300 sec [86-154 sec]), but not to 
adenosine diphosphate (70 sec [73-129 sec]). Platelet aggregation responses to collagen, 
arachidonic acid, adenosine diphosphate, and ristocetin were normal; rate of aggregation and 
final amplitude to epinephrine were decreased. Whole mount platelet electron microscopy 
testing showed virtually no delta granules (Figure 1E).
Pulmonary function and six-minute walk test were normal. High-resolution computed 
tomography scan of the chest showed bibasilar juxta-pleural linear and nodular atelectasis 
without clear evidence of interstitial lung disease (Figure 1F).
Mutation Identification
Given her findings of mild oculocutaneous albinism and history of excessive bleeding with 
absent platelet delta granules, the patient was diagnosed with HPS. To determine her HPS 
subtype, SNP analysis and exome sequencing were performed. Consistent with a history of 
consanguinity, SNP analysis showed regions of homozygosity, one of which included HPS1 
and HPS6. PCR showed normal full length HPS1 transcript (data not shown). A targeted 
NGS panel of 9 HPS genes using the patient’s genomic DNA identified a homozygous 
mutation in HPS6 (NM_024747.5:c.383T>C; p.V128A). This variant is not found in 
published reports of HPS6 mutations (Table 1), and it is not reported in the large population 
genetics databases 1000 Genomes, NHLBI GO Exome Sequencing Project (ESP), or 
Genome Aggregation Database (gnomAD). Furthermore, this HPS6 mutation is predicted to 
be probably damaging by PolyPhen-2 (v2.2.2r398) Hum Var (score 0.921), deleterious by 
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Sorting Intolerant from Tolerant (SIFT, score: 0.01), and disease causing by MutationTaster 
(prob value = 0.964).
Cellular Expression of HPS6
To determine whether the patient’s mutation is associated with altered HPS6 expression, 
mRNA and protein levels were measured in her cells. We found that HPS6 mRNA levels in 
this patient’s dermal fibroblasts were 37% of that in normal cells (p<0.001) and 36% of that 
in HPS-1 BLOC-3 complex controls (p<0.001)(Figure 1G). Western blot analysis showed 
that HPS6 protein expression in the patient’s fibroblasts were 60% of that of normal controls 
(p<0.001) and 29% of that of HPS-1 BLOC-3 complex controls (p=0.008)(Figure 1H). 
HPS1 and HPS4 proteins were expressed in this HPS-6 patient’s cells; these results are 
consistent with this patient’s defect in BLOC-2, and not BLOC-3.
Discussion
Hermansky-Pudlak syndrome type 6 was diagnosed in a 58-year old woman with a history 
of severe bleeding and without overt oculocutaneous albinism. Patients with HPS-6 
generally have mild hypopigmentation and bleeding compared to patients with other HPS 
subtypes, and pulmonary fibrosis has not been reported in patients with HPS-6 (Huizing, 
2009; O’Brien, 2016). However, this patient’s oculocutaneous albinism was atypical, 
because it was asymptomatic. Indeed, her findings of albinism were only identified by 
comprehensive ophthalmologic examination. In contrast to her subclinical oculocutaneous 
albinism, this patient had severe bleeding, including some instances of hemorrhage requiring 
blood product transfusions and an episode of prolonged gastrointestinal bleeding with 
hemodynamic instability. HPS-6 was reported in a 32-year old male with hemophilia B who 
also had excessive bleeding, but the patient’s oculocutaneous albinism facilitated a diagnosis 
of HPS in that case (O’Brien, 2016).
The diagnosis of HPS-6 in our patient is based upon findings of absent platelet delta 
granules, identification of a homozygous missense variant in HPS6 predicted to be 
deleterious, and molecular studies showing reduced HPS6 expression in the patient’s cells. 
NGS analysis showed a single missense variant in HPS6 in a highly conserved region of 
HPS6. Consistent with predictive algorithms, HPS6 mRNA and protein levels are 
significantly reduced in this patient’s cells. It is possible that this patient’s subclinical 
oculocutaneous albinism is a consequence of sufficient, albeit low, amounts of HPS6 protein 
in pigment-producing cells in her skin, hair and eyes.
Identifying a patient’s HPS subtype has clinical relevance. For example, some 
manifestations of HPS are subtype-specific, including progressive pulmonary fibrosis. 
Although fibrotic lung disease is a leading cause of death in patients with HPS-1, HPS-2, or 
HPS-4, patients with HPS-6 have not been reported to develop pulmonary fibrosis (Huizing, 
2009; Huizing, 2017; Gochuico, 2012; O’Brien, 2016). This patient’s imaging studies 
revealed no clear evidence of interstitial lung disease, which is consistent with a diagnosis of 
HPS-6. In addition, establishing a diagnosis of HPS in this patient will also facilitate 
management of her bleeding diathesis. In general, treatment of bleeding in patients with 
HPS includes thrombin-soaked gelfoam for skin wounds, intravenous desmopressin for 
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invasive procedures, and judicious transfusion of platelets to prevent or treat surgical 
bleeding (Huizing, 2017).
In conclusion, we report a novel homozygous c.383T>C missense variant in HPS6 
associated with low cellular levels of HPS6 mRNA and protein in an individual with 
subclinical oculocutaneous albinism and a history of severe bleeding. Genetic testing and 
platelet electron microscopy studies combined with molecular analysis in some cases are 
useful modalities to evaluate and diagnose HPS in patients with atypical clinical features.
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Figure 1. 
Clinical and molecular features of patient with Hermansky-Pudlak syndrome type 6. (A) 
Pedigree shows proband (arrow) with Hermansky-Pudlak syndrome-6 (HPS-6) and 
consanguinity. (B) Anterior segment photos show absent iris transillumination defects in a 
normal volunteer (left panel). Mild transillumination defects, seen as dark red scattered 
across the iris in both the right (middle panel) and left (right panel) eyes were present in this 
patient with HPS-6. (C) Wide field images of the retina demonstrate normal pigmentation in 
a healthy volunteer (left panel) in contrast to the minimally pigmented peripheral retina with 
visible choroidal vasculature (black arrows) due to lack of pigmentation in the patient’s right 
and left eyes (middle and right panels, respectively). (D) Optical coherence tomography 
shows a normal fovea in the healthy volunteer (left panel), while the patient’s fovea shows 
grade 3 foveal hypoplasia with loss of the foveal depression (white arrow), no outer segment 
lengthening relative to the parafoveal outer nuclear layer, and no extrusion of the plexifom 
layers (middle and right panels). (E) Representative platelets from this patient with absent 
dense granules are shown by whole mount electron microscopy (left panel; size bar = 800 
nm) and normal alpha granules by thin-section transmission electron microscopy (right 
panel; size bar = 2 um). (F) Representative high-resolution computed tomography scan 
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image of the chest reveals right juxtapleural linear and nodular atelectasis (solid white 
arrow) without evidence of interstitial lung disease. (G, H) Expression of HPS6 mRNA and 
HPS6 protein in this patient’s dermal fibroblasts is significantly reduced compared to that in 
cells from two normal controls or three patients with HPS-1. Western blots for HPS6, HPS1, 
HPS 4 and beta actin are shown. Open arrow indicates band corresponding to HPS1 protein.
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Table 1.
Reported Variants in HPS6
Variants Age, Gender† Ethnicity/Nationality Consan‡ Reference(s)
c.383T>C 58, F Caucasian Yes This report
c.1066_1067insG varied Israeli Bedouin Yes Huizing, 2017; Schreyer-Shafir, 2006
c.1114 C>T 32 y, M Caucasian No O’Brien, 2016
c.238dupG; c.815C>T 13 y, F German/Dutch NA Huizing, 2009
c.223C>T; c.1234C>T 52 y, M Italian NA Huizing, 2009
c.913C>t; del 9,972-bp 22 y, M Scottish/English/German NA Huizing, 2009
c.1865_1866delTG 36 y, F Irish/German NA Huizing, 2009
c.1713_1716delTCTG 39 y, F Belgian No Zhang, 2003
c.87_108ins22 1 y, F Caucasian No Radke, 2013
c.779G>A 1 y, F Punjabi Afghan Yes Hull, 2016
c.902dupT; c.1083dupC 5 mo, M Punjabi Afghan Yes Hull, 2016
c.64_65insGCGGC; c.155del 1 y, M Chinese NA Wei, 2016
c.64_65insGCGGC; c.1513C>T 6 y, M Chinese NA Wei, 2016
c.895C>T; c.1372delG 5 y, M Chinese NA Wei, 2016
c.1898delC 3 y, F Japanese No Miyamichi, 2016
c.2038C>T 11 mo, F Japanese No Miyamichi, 2016
c. 60_64dupGCGGC; c.2038C>T 9 y, F Japanese NA Okamura, 2018
†
F, female; M, male; mo, months; y, years
‡
consanguinity; NA, not available
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